Board of Directors

Prakash Gowd
Independent Director (Audit Committee, Disclosure Policy Committee)

Mr. Gowd is an accomplished executive with over 25 years of experience in biopharma, capital markets, and entrepreneurship. His career spans startups and large corporations, expertise in various healthcare verticals, leading people, strategy, P&L, financing, licensing, M&A, and go-public transactions. Currently, as Vice President at TIAP (Toronto Innovation Acceleration Partners), he drives transformation of early-stage medical innovations into successful companies. Previously, Mr. Gowd was Chief Operating Officer and Head of Corporate Development at a mental health company, leading its U.S. operations, public listing, acquisitions, and eventual sale. He also co-founded a genetic testing company in medical cannabis, successfully building and selling the business. Mr. Gowd has held senior roles in biotech equity research and investment banking at major financial institutions and started his career in pharmaceutical commercial operations and new product development. Mr. Gowd currently serves on the Board of Directors of HDAX Therapeutics Inc., a privately held biotechnology company, and Appili Therapeutics Inc., a TSX-listed biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Mr. Gowd holds an MBA from McGill University, a Pharmacy degree from the University of British Columbia, and a Chartered Director designation.

Joseph Arcuri
Independent Director (Audit Committee - Chair, Disclosure Policy Committee - Chair)

Mr. Arcuri, CPA, CA, brings audit and accounting expertise to the Board as well as significant executive leadership experience. Mr. Arcuri currently serves as Chief Financial Officer of NRStor Inc., which provides energy storage project development and construction services.

He previously served as Executive Vice President, Operations and Finance, Content Group, at St. Joseph Communications, a marketing communications firm. Between 2013 and 2016, Mr. Arcuri served as Chief Operating Officer and Chief Financial Officer at TableRock Media Ltd., a streaming service company. In 2012, Mr. Arcuri was Chief Financial Officer of GlassBOX Television Inc., a television service provider.

Between 2007 and 2011, Mr. Arcuri was President of AOL Canada Inc., an internet service provider and previously led Bell Canada’s managed services group. Mr. Arcuri started his professional career with PricewaterhouseCoopers within its assurance group and later transferred to its valuation, and mergers and acquisitions service team. He is also currently the voluntary Chair of Villa Charities Inc.

Sara Elford
Independent Director (Audit Committee, Disclosure Policy Committee, Nominating Committee - Chair)

Ms. Elford is a Corporate Director who brings a wealth of capital markets and corporate governance experience to the Board. In addition to BioSyent, she is a member of the Board of Directors of BQE Water Inc., a TSX Venture Exchange (“TSXV”) listed company specializing in water treatment and management; EcoSynthetix Inc., a TSX listed company specializing in renewable chemicals; and Xebec Adsorption Inc., a renewable gas equipment and service company. Ms. Elford previously served on the Board of Directors of Hydrogenics Corporation (2016-2019), a hydrogen technology company, Carmanah Technologies Corporation (2015-2019), a solar LED technology company, TSO3 Inc. (2019), a medical device sterilization technology company, Pure Technologies Ltd. (2015-2017), a pipeline leak detection technology company, and WeCommerce Holdings Ltd. (2020-2022), a TSX Venture Exchange listed ecommerce software company.

Between 1995 and 2015, Ms. Elford was a Director and Research Analyst with Canaccord Genuity Group Inc. and previously served in investment banking roles with Kidder Peabody and Wood Gundy. Ms. Elford earned her Chartered Financial Analyst designation in 1997.

René C. Goehrum
Chairman of the Board of Directors

René Goehrum is an experienced entrepreneur, leader and business builder with over thirty years of experience in marketing, sales, operations and corporate and business development in pharmaceuticals and consumer products. Previously, Mr. Goehrum was the President and a co-founder of Bratch Goehrum Inc., a professional services firm that provided marketing and sales services to clients such as Procter & Gamble, Boehringer Ingelheim, Sandoz (n.k.a. Novartis), Kraft Foods, Coca Cola, and H.J. Heinz Company. He started his career with Procter & Gamble, a world leader in marketing consumer and healthcare brands.

Mr. Goehrum currently also serves as the President and Managing Director of Aquiam Partners Ltd., a private equity firm.

Peter Lockhard
Independent Director (Lead Director, Compensation and Human Resources Committee)

Mr. Lockhard has significant sales, marketing, operations and corporate strategy experience from his career as a business leader and builder.  From 2005 – 2020, Mr. Lockhard was a member of the executive leadership team of Points International Ltd., a TSX and NASDAQ-Listed international e-commerce company in the loyalty rewards industry (which was acquired and taken private in June 2022), where he served as Chief Operating Officer (2009 – 2020), Chief Revenue Officer (2007 – 2009) and VP Business Solutions (2005 – 2006). During his tenure, Mr. Lockhard helped to grow the revenue of Points International Ltd. from $US 10 million to $US 400 million.

Mr. Lockhard is also a Managing Director of Aquiam Partners Ltd., a private equity firm.

Stephen Wilton
Independent Director (Compensation and Human Resources Committee)

Mr. Wilton brings extensive product development and regulatory expertise to the Board, from a long and varied career in the pharmaceutical industry.

A licensed pharmacist, Mr.  Wilton earned a B.Sc. in Pharmacy from the University of Toronto and started his career working as a pharmacist in community and hospital pharmacy. After working in medical sales and marketing positions at Eli Lilly Canada he joined AstraZeneca. While at AstraZeneca, Mr. Wilton held leadership positions in Marketing where, as Executive Director, he led a team managing a $300 million specialty product portfolio, as well as three other assignments as Executive Director of Business Development, Executive Director of Pricing, Reimbursement and Healthcare Solutions, and Director of Regulatory Affairs.

After his seventeen-year career at AstraZeneca, Mr. Wilton worked as Vice President of Pharmacy Affairs for the Canadian Association of Chain Drug Stores representing the interests of owners and pharmacists in the Canadian healthcare system. Mr. Wilton, also holds an MBA from York University (Schulich School of Business).